Katherine Tai Holds Ground on Free Trade, Market Access, in Senate Finance Hearing
Members of the Senate Finance Committee try convincing USTR Katherine Tai of the importance of free trade. She explains why, and where, that might not work.
Drug Shortages: Why They Happen, What Can Be Done About Them?
A Senate hearing on pharmaceutical shortages discusses America’s dependence on India and China, and what can be done to reshore.
Senate Banking Committee Asks: Should China be Allowed to Buy U.S. Farmland?
Should China be allowed to buy U.S. farmland? What about agribusiness operations that are near military installments?
Why Medicine Costs So Much Money, Despite Imports from Low-Cost Nations
The Senate Commerce Committee takes the little known, and even less understood, Pharmacy Benefit Manager industry to task for high drug costs.
Senate Hearing Bemoans Worker Shortages, Wonders If Reshoring Can Work
A Senate Commerce subcommittee hearing heard from witnesses who said worker shortages will ultimately be a drag on U.S. reshoring efforts. Pharmaceutical reps warned of high energy costs, which could add to import dependence.
Senate Finance Committee Chairs Want Bigger Trade Deals to Counter China
Senator Cornyn calls for large trade agreements to counter China in latest hearing on international trade inside the Senate Finance Committee.
Senate Banking Committee Debates U.S. Corporate Investment in China
Should U.S. companies like Intel be allowed to invest in factories and partner with tech companies in China? If so, should there be restrictions?
JP Morgan CEO Jamie Dimon, Others, Tell Congress They’ll Leave China If Told
Washington proves to be more hawkish on China than Wall Street. Especially in the House of Representatives. A look at a recent House Financial Services Committee meeting.
Katherine Tai Defends Section 301 China Tariffs in Senate Hearing
In one of her best hearings yet, USTR Katherine Tai holds fast on why the U.S. needs the Section 301 tariffs on China.
FDA Advancements Act Passes Committee, Sets Stage for Fall Reauthorization Passage
The FDA Safety and Landmark Advancements (FDASLA) Act has passed a key committee, with 25 out of some 30 amendments passing. Generics and baby formula crisis got most of the attention.